Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609) . The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688) . Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) [1][2].

Product Specifications

CAS Number

[220578-59-6]

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gemtuzumab-ozogamicin.html

Purity

98.00

Solubility

H2O

Smiles

[Gemtuzumabozogamicin]

Molecular Weight

151000 (average)

References & Citations

[1]Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11 (6) :549-559. |[2]Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150 (7) :1141-1155.|[3]McGavin, J. K., & Spencer, C. M. (2001) . Gemtuzumab ozogamicin. Drugs, 61 (9), 1317–1324.|[4]Petrich, T., et al., (2010) . In vitro experimental (211) At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. European journal of nuclear medicine and molecular imaging, 37 (5), 851–861.